EFFECT OF PERFLUOROCARBON ON PULMONARY SURFACTANT. AN ELECTRON

MICROSCOPICAL AND STEREOLOGICAL STUDY MiRodiger, S Wendt², L Köhe², W Burkhardt¹, R R Wauer¹, M Ochs^{2 1} Clinic for Neonatology, Charité-Mitte, Berlin, Germany; ²Department of Anatomy, Division of Electronmicroscopy, Göttingen, Germany **Background**: Partial liquid ventilation (PLV) represents an alternative therapy of severe respiratory insufficiency, caused by disturbances of the pulmonary surfactant. To wean patients from PLV an intact surfactant system is required. Data concerning the interaction of perfluorocarbons (PFC) with surfactant metabolism are controversial. According to in

Data concerning the interaction of perhapsications (FC) with stratactant metazonism are considered and according to in vitro data we hypothesized that intracellular surfactant pool is reduced in PLV reated animals. Methods: Prospective, randomized animal study on male wistar rats. Surfactant depleted rats were treated with either PLV (Lavaged-PFC, n=5) or conventional mechanical ventilation (Lavaged-Air, n=5) for 1 hour. For control, 10 healthy animals with air (Healthy-Air, n=5) or PFC filled lungs (Healthy-PFC, n=5) were studied. A design-based stereological approach was used for quantification of lung parenchyma and the intracellular and intraalveolar surfactant pool at the light and electron microscopic level.

Results: Compared to Healthy-lungs, Lavaged-animals had more type II cells with lamellar bodies in the process of Results: Compared to Healthy-lungs, Lavaged-animals had more type II cells with lamellar bodies in the process of secretion and freshly secreted lamellar body like surfactant in the alveoli. Fraction of surfactant covered alveolar epithelial surface area and total intraalveolar surfactant content were significantly smaller in Lavaged-animals. Compared with Air-filed lungs, both PFC-groups had a significantly higher total lung volume, but no other differences. Conclusion: In contrast to the hypothesis, short term PLV in surfactant depleted animals neither affects the intracellular and intraalveolar surfactant composition nor the surfactant content.

232

TREATMENT OF CHRONIC LUNG DISEASE ASSOCIATED PULMONARY HYPERTEN-

SION WITH INHALED NITRIC OXIDE ADMINISTERED VIA NASAL CPAP <u>F Sandri</u>¹, G Ancora¹, G Bronzetti², M G Capretti¹, R Sciutti³, C Massardo⁴ ¹Neonatology, Pediatrics, Bologna, Italy; ²Pediatric Cardiology, Cardiology, Bologna, Italy; ³Pediatric Radiology, Radiology, Bologna, Italy; ⁴INO Therapeutics, NG T INO Therapeutics, Milano, Italy Background: Pulmonary hypertension (PH) is a major complication of chronic lung disease (CLD), and its treatment

is based on the use of oxygen. Inhaled nitric oxide (iNO) is a highly selective pulmonary vasodilator and it has been used

Background: Pulmonary hypertension (PH) is a major complication of chronic lung disease (CLD), and its treatment is based on the tues of oxygen. Inhaled nitric oxide (iNO) is a highly selective pulmonary vasodilator and it has been used in the therapy of this condition via endotrachal tube during mechanical ventilation. Its use in CLD associated PH with non-invasive delivering methods has not yet been documented to our knowledge. Methods: We report the case of a newborn born prematurely (GA 27 wks BW 475 gms) who developed CLD. At 43 wks post conceptional age oxygen need increased to FiO2=0.7 in nasal CPAP (nCPAP) to maintain O2 saturation (SaO2) within the normal range. Chest X-ray showed cardiomegaly (CTI=0.66). Echocardiography showed indirect signs of PH (hypertrophy of the right ventricle, systolic "D" shaped interventricular septum, moderate pulmonary valve insufficiency) and the value of the mean pulmonary arterial pressure (mPAP) measured through pulmonary insufficiency (PI) was 40–45 mm Hg immediately before starting iNO 1. NO (INOmax-INO Therapeutics) was administered via nCPAP (Infant Flow System-EME) in conjunction with a iNO delivery system (INOvent-Datex Ohmeda) at a starting does of 10 ppm. **Results:** 5 minutes after starting iNO at 10 ppm via nCPAP, echocardiography showed a decrease of mPAP to 14–15 mm Hg and a significant reduction of PI. After 30 min the oxygen need decreased to FiO2=0.5 to keep So20 normal. Subsequently the dose of iNO was progressively decreased with no rebounds in mPAP and stopped 13 days from the start. A th the end of treatment echocardiography showed a stable mPAP of 14–15 mm Hg. Met Hb on blood and NO2 in the inspiratory line of nCPAP circuit were never beyond safety levels. On the fifth day of iNO treatment, therapy with decamethasone was started at the dose of 0.25 mg/kg/day in two doses. Dexamethasone dose was progressively decreased and stopped the days after the start of iNO treatment echocardiographie PH was absent, chest X-ray showed a reduction of cardiomegaly

ciated with CLD.

230

HUMAN MILK AS A NATURAL SOURCE OF ANTI-ANGIOGENIC COMPOUNDS <u>S Rudloff</u>¹, D Schneider², C Kunz¹, R G Bretzel², T Linn² ¹Justus-Liebig-Universitäi Giessen, Department of Pediatrics and Neonatology, Giessen, Germany; ²Justus-Liebig-Universitäi Giessen, Department of Internal Medicine, Giessen, Germany; ³Justus-Liebig-Universitäi Giessen, Institute of Nutritional Science, Giessen, Germany Background: Human milk feedings are thought to reduce certain health risks such as the development of retinopathy background: Human milk feedings are thought to reduce certain health risks such as the development of retinopathy

due to hyperoxia and neovasularization in the neonatal period. As a new approach for the prevention and therapy of diseases involving the formation of new blood vessels, synthetic oligosaccharide ligands for cell adhesion molecules revealed anti-angiogenic effects in *virus*. Human milk, however, is a natural reservoir of oligosaccharides structurally resembling selectin ligands such as the tetrasaccharide sialyl-Lewis x. Here, we assessed the properties of human milk oligosaccharides

selectin ligands such as the tetrasaccharide stalyLewis X. Here, we assessed the properties of human milk oligosaccharides to modulate angiogenesis in *vitro* and in *vito*. **Methods:** In vitro tube formation assays were performed using bovine retinal endothelial cells (BREC) on collagen-coated dextrane beads in fibrin gels containing isolated neutral (nHMO) or sialylated human milk oligosaccharides (sHMO) at concentrations of 10, 25, and 100ig/mL. After 48h incubation tubular structures radiating from the beads' surface and protruding into the gel were counted. To confirm the anti-angiogenic capacity of HMO in vivo, MatrigelTM plugs (containing heparin, VEGF and bFGF) supplemented with 100ig/mL of nHMO or sHMO were subcutaneously injected in vitro. The relation of the formation of the counted of the one of the interaction for the formation of the formation of the delated effect of the neutron of the formation of the delated effect of the neutron of the neutron of the formation of the delated effect of the neutron of the neutron of the neutron of the neutron of the formation of the for mice. The gel plugs were recovered five days after implantation and inspected for the formation of blood filled microvessels

microvessels. Results: In contrast to nHMO, sHMO showed anti-antigenic potency in a concentration dependent manner with a maximum effect of about 40% at 25ig/mL. The differences of the effects of nHMO and sHMO were significant at 25ig/mL (p<0.05) and 100ig/mL (p<0.05). While the nHMO containing plug showed high cellularity and was partially congested with blood, the plug spiked with sHMO was transparent indicating the inhibition of neovacularization. Conclusion: Human milk oligosaccharides containing sialic acid revealed anti-angiogenic properties *in vitro* and *in vivo*

. These potentially beneficial effects may explain why diseases associated with angiogenesis such as retinopathy were reported to be less prevalent in breastfed infants.

231

A RARE CAUSE OF SEVERE PERSISTENT PULMONARY HYPERTENSION OF THE

A KARE CAUSE OF SEVERE FERSISTENT FURNINARY INTERTENTION OF THE NEWBORN: THE AGENESIS OF THE DUCTUS VENOSUS G Ancora¹, C Locatelli¹, G Piln², P Falca², G Bronzetti³, <u>F</u> <u>Sandri¹</u> Neonatology, Pediatric, Bologna, Italy; ²Obstetric and Gynaecology, Obstetric and Gynaecology, Bologna, Italy; ³Pediatric Cardiology, Cardiology, Bologna, Italy; Background: Persistent pulmonary hypertension of the newborn (PPIN) can be primitive or a consequence of many lung diseases. We report the occurrence of PPIN after a rare disease: agenesis of the ductus venosus (ADV). Ductus venosus (DV) is a fetal vessel draining 20–30% of the oxygenated umbilical veni hood into the inferior vena cava bypassing the liver. Absent DV can be associated with a normal or abnormal umbilical veni concient to the portal vein. cava or into the right atrium. ADV can be associated with hydrops, chromosomal anomalies, atrial septal defects, facial clefts, kidney anomalies (1).

Methods:Between 2000 and 2003, 6 cases of ADV (GA 31-37 weeks) with umbilical vein drainage into the right atrium Recurst in 4 cases PPHN, as shown by echocardiography, developed after birth; cardiomegaly was present in uterus but

Resting: in eases performed as shown by economic paper, developed and built, candonic galy was present in ductus out no hydrops. In two newborns PPHN was severe and required inhaled nitric oxide (NO); in the remaining a newborns mechanical ventilation and vasoactive amines were able to reat PPHN. Two newborn showed no cardiorespiratory diseases: one showed policytemia and the other mild hypoglicemia. Outcome was good in 5 newborns; in one severe encephalomalacia followed profound hypoxemia during PPHN. To our knowledge this is the first report of severe PPHN in newborns with ADV. Two main pathogenetic factors can explain this association: 1) liver bypassed by the oxygenated umbilical veries flow can result in liver hypoxia and/or in absent liver metabolism of vasoactive substances. It has been demonstrated that hypoxia enhances endothelin-1 (ET-1) gene expression in the liver (2); moreover, PPHN was found while a liver provide the endoted on the provide section of the provide section of the section of the section of the provide section of the provide section of the section of the provide section of the provide section of the section of the provide section of the section of the section of the provide section of the provide section of the section of the provide section consistence unit reports characteristic indication (1, 1, 2) gene expression in the rest (2), indicates, restrict a shared in a child with congenital porto-caval shunt suggesting a pathogenetic role for twice metabolities reaching the pulmonary vascular bed (3); 2) in fetuses with ADV increased right cardiac output has been reported (1). Increased pulmonary blood flow can decrease NO production and increase ET-1 level in the lung as well as ET-1 receptors mediating vasoconstriction

Conclusion:Severe PPHN can complicate ADV. Timely and aggressive treatment of PPHN in such cases can lead to normal outcome. Understanding of the pathogenesis can help to optimise therapy.

References:


Jaeggi Et et al. Am J Obstet Gynecol 2002;187:1031
Ritthaler T et a. Eur J Physiol 1996 ;431:587
Ersch J et al. Eur J Pediatr 2002;161:660

- 4. Black SM et al. Circulation 2003;108:1646

233

FAECAL CALPROTECTIN LEVELS AT TWO MONTHS OF AGE IN HEALTHY INFANTS

Status Contention of the Description of Description Description of Description of Description of Description of D



234

 SURGICAL CLOSURE OF A PATIENT DUCTUS ARTERIOSUS (PDA) IS ASSOCIATED WITH INCREASED NEURO-SENSORY IMPAIRMENT IN EXTREMELY I OW BIRTH WEIGHT (ELBW) INFANTS: RESULTS FROM THE TRIAL OF INFORMATION INFO 18-month outcome. Results: The results are summarized in the table.

Outcome	PDA Subgroup	Event rate	Unadjusted Odds ratio		Adjusted Odds ratio	
			OR	P value	OR (95% CI)	p value
Death or neurosensory	No PDA Non-surgical PDA Surgical PDA	307 / 708 (43%) 154 / 315 (49%) 66 / 111	0.8 -1.5	0.06 -0.07	1.0 (0.8–1.4) -1.4 (0.92.2)	0.88 -0.17
impairment	Sugical TDA	(59%			(0.94.2.2)	
Death	No PDA Non-surgical PDA Surgical PDA	141 / 737 (19%) 70 / 329 (21%) 16 / 114 (14%)	0.9 -0.6	0.45 -0.10	1.3 (0.9–1.8) -0.5 (0.3–0.9)	0.18 -0.02
Neurosensory impairment	No PDA Non-surgical PDA Surgical PDA	162 / 567 (29%) 84 /245 (34%) 50 / 95 (53%)	0.8 -2.1	0.10 -0.002	0.9 (0.6-1.3) -1.9 (1.2-3.1)	0.52 -0.01

There was a significant direct correlation between the rates of surgical PDA closure in individual study centres and the prevalence neuroesnory impairments in survivors (p=0.032). **Conclusion:**Surgical PDA closure was associated with reduced mortality but increased neurosensory impairment in ELBW infants, remains uncertain whether PDA ligation is a cause or a marker of adverse long-term outcome in this population.